Ropes & Gray advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, a horizontal platform for cell programming, signed an agreement with Bayer to expand Ginkgo’s platform capabilities...
You must be a Standard 1 Year member to access this content.
Freshfields advised Zymergen Inc. (Nasdaq: ZY) on the deal, while Ropes & Gray advised Ginkgo Bioworks. Zymergen Inc. (Nasdaq: ZY), a biotechnology company that uses a...
You must be a Standard 1 Year member to access this content.
Ropes & Gray, working alongside Walkers, represented Pfizer, while Skadden advised Centerview Partners, the financial advisor to Biohaven Pharmaceutical on the deal. S&C, Maples and Calder...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Pfizer Inc. in the deal, while Cooley represented Arena Pharmaceuticals. Debevoise & Plimpton advised Evercore Group and Guggenheim Securities as financial advisors...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Pfizer in the deal. Pfizer announced its collaboration arrangement with Biohaven Pharmaceutical Company to commercialize rimegepant, a therapy approved in the U.S. as...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised National Resilience on the deal. National Resilience, Inc., a biopharmaceutical manufacturing specialist, closed a strategic alliance with bluebird bio, Inc., to accelerate...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
